Carl Fichtenbaum

Carl J. Fichtenbaum , MD

Professor of Clinical

Associate Chairman of Medicine for Translational Research

UC Health Holmes Hospital
Room 3114
Albert Sabin Way at Eden Avenue
Cincinnati, Ohio 45219
Phone 513-584-6977
Fax 513-584-6386
Email carl.fichtenbaum@uc.edu

Professional Summary

Dr. Fichtenbaum's expertise is in clinical research in infectious diseases, in particular complications of HIV, antiretroviral therapy, dyslipidemia and cardiovascular disease. Dr. Fichtenbaum is Principal Investigator of the AIDS Clinical Trials Unit at UC. He is Principal Investigator of Sexually Transmitted Infections Grant.  He is board certified by the American Board of Internal Medicine and Infectious Diseases. Dr. Fichtenbaum has been elected as a Fellow to the American College of Physicians, HIV Medical Association, and Infectious Diseases Society of America. His published works include approximately more than 100 articles, 75 abstracts and various reviews, book chapters and letters.

Education

Bachelor's Degree: University of Missouri 1983 (Biology)

Medical Degree: University of Missouri 1985

Residency : Bridgeport Hospital 1989 (Internal Medicine / Pediatrics)

Chief Medical Residency : Bridgeport Hospital 1990 (Chief Medical Residency)

Fellowship: Yale University School of Medicine 1991 (AIDS Clinical Fellow)

Fellowship: Barnes Hospital/Washington University School of Medicine 1994 (Infectious Diseases)

Fellowship: National Institute of Drug Abuse 1994

Certifications

American Board of Internal Medicine (Infectious Disease) (Certification Date: 11-10-1994 ) - (Recertification Date: to 12-31-2014 )

American Board of Internal Medicine (Certification Date: 09-13-1989 )

Clinical Interests

Infectious Disease

Pediatrics

Specialities

Infectious Disease

Internal Medicine

Pediatrics

Research and Practice Interests

HIV, STDs And Other Selected Infectious Diseases

Positions and Work Experience

1989 -1990 Clinical Instructor, Yale University School of Medicine,

1990 -1991 Post-Doctoral Fellow, Yale University School of Medicine,

1991 -1994 Fellow in Medicine, Washington University School of Medicine,

1993 -1996 Instructor of Medicine, Washington University School of Medicine,

1996 -1999 Assistant Professor of Medicine, Washington University School of Medicine,

1999 -2006 Associate Professor of Clinical Medicine, University of Cincinnati,

2006 - Professor of Clinical Medicine, University of Cincinnati,

2012 - Associate Chairman for Translational Research, University of Cincinnati, Department of Internal Medicine

Research Support

Grant: #1 U01 AI069513 Investigators:Fichtenbaum, Forrester 12-01-2007 -11-30-2013 NIH/NIAID AIDS Clinical Trials Group Role:PI $997,057 Active

Grant: #1 T01 AI1068524 Investigators:Chougnet, Fichtenbaum 08-01-2006 -07-31-2011 NIEHS Role of Regulatory T Cells in HIV Infection Role:Investigator $14,549 Active

Grant: #5 H76HA0111 Investigators:Kaul, Fichtenbaum, Forrester, Haglund 01-01-2007 -12-31-2011 DHHS/HRSA Cincinnati Health Network, Ryan White Title III Funds Role:Co-PI $582,753 Active

Grant: #5 U01 NS032228-12 Investigators:Clifford, Fichtenbaum 12-01-2009 -11-30-2011 National Institute of Neurological Disorders & Stroke Washington University Neurological AIDS Research Consortium Role:Investigator $11,000 Active

Grant: #1 R56A1087462-01A1 Investigators:Lyons, Fichtenbaum 09-15-2010 -08-13-2011 NIH/NIAID Transmission Network Targeting Adjunct to Emergency Department Screening Role:Investigator $19,794 Active

Grant: #U10 DA013732 Investigators:Somoza, Fichtenbaum 09-15-2010 -08-31-2011 NIDA Clinical Trials Network Ohio Valley Node Role:Investigator $2,807,592 Active

Grant: #000059 Investigators:Fichtenbaum, Carl 01-01-2006 -12-31-2006 Health Resources and Services Administration Community HIV comprehensive Care Program Role:PI $547,000.00 Closed Level:Federal

Grant: #CHMC 103666 Investigators:Fichtenbaum, Carl 08-01-2006 -07-31-2011 National Institute of Allergy and Infectious Diseases Role of Regulatory T Cells in HIV Infection Role:PI $134,932.00 Closed Level:Federal

Investigators:Fichtenbaum, Carl 04-01-2002 -03-01-2005 Research Triangle Institute RTI AIDS/Cancer Cohort Study Role:PI $8,410.00 Closed Level:Private Non-Profit

Grant: #CHMC 430 / R01 AI056927 Investigators:Fichtenbaum, Carl 01-01-2005 -12-31-2009 National Institute of Allergy and Infectious Diseases CD40 Ligand Dysregulation and HIV Pathogenesis Role:PI $148,850.00 Closed Level:Federal

Grant: #7-R01-DA-09825-04-A0-S0-E0 Investigators:Fichtenbaum, Carl 08-01-1999 -07-31-2000 National Institute on Drug Abuse Epidemiology and Outcome of STDS in Drug Users Role:PI $62,734.00 Closed Level:Federal

Grant: #SRS 004193 Investigators:Fichtenbaum, Carl; Sharma, Sonia 04-05-2007 -06-30-2008 Bristol-Myers Squibb Co. Lower HDL and Elevated Triglycerides Predict HIV-Associated Lipoatrophy Role:PI $15,000.00 Closed Level:Industry

Grant: #BRS-ACURE-Q-06-0000164 (Master Agreement) / U01 AI068636 Investigators:Feinberg, Judith; Fichtenbaum, Carl 07-01-2006 -05-31-2013 National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Network Role:PI $424,732.44 Closed Level:Federal

Grant: #CRB-DCR01-S-09-00319 / HHSN272200900001/2/3I Investigators:Feinberg, Judith; Fichtenbaum, Carl 11-01-2009 -03-31-2013 National Institute of Allergy and Infectious Diseases SSS Master Agreement Role:PI $304,161.85 Active Level:Federal

Grant: #CRB-UCLA-S-10-00045 / R01 HL095132 Investigators:Fichtenbaum, Carl 06-01-2009 -06-30-2012 National Heart, Lung and Blood Institute Cardiovascular, Anthropometric, and Skeletal Effects of Anti-Retroviral Initiation with Tenofovir/Emtricitabine plus Atazanavir/Ritonavir, Darunavir/Ritonavir or Raltegravir Role:PI $56,840.00 Active Level:Federal

Grant: #WU-10-197 Investigators:Fichtenbaum, Carl 12-01-2009 -11-30-2011 National Institute of Neurological Disorders and Stroke Neurologic AIDS Research Consortium - Washington University Sub Role:PI $17,270.00 Closed Level:Federal

Grant: #CRB-UWAS1-S-11-0027 / HL095126 Investigators:Fichtenbaum, Carl 07-01-2010 -06-30-2012 National Heart, Lung and Blood Institute Carotid Artery Intima Media Thickness and Brachial Artery Imaging Role:PI $6,260.00 Active Level:Federal

Grant: #BRS-ACURE-S-12-002363 Investigators:Fichtenbaum, Carl 01-01-2012 -05-31-2014 Aids Clinical Trials Group Network A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maravirco-Containing Role:PI $4,640.00 Active Level:Private Non-Profit

Grant: #BRS-ACURE-S-12-00214 Investigators:Fichtenbaum, Carl 06-01-2011 -05-31-2013 Bristol-Myers Squibb Co. A Prospective Randomized Pilot Trial of High Dose Vitamin D and Calcium for Bone Health in HIV Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART) Role:PI $1,500.00 Active Level:Industry

Grant: #BRS-ACURE-S-12-000604-002301 Investigators:Fichtenbaum, Carl 06-01-2011 -05-31-2012 National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Network Role:PI $393.00 Closed Level:Federal

Grant: #CHN Sub \ H76HAO0111 Investigators:Feinberg, Judith; Fichtenbaum, Carl; Forrester, Jennifer; Grubbs, Peter; Haglund, Lisa; Johnson, Kay; Kaul, Pamposh 04-01-2012 -03-31-2014 Health Resources and Services Administration Community HIV Comprehensive Care Program Role:Collaborator $1,165,506.00 Active Level:Federal

Grant: #CRB-SSS-S-12-00296 Investigators:Fichtenbaum, Carl 05-01-2012 -05-31-2013 Merck Sharp & Dohme Corp Aids Clinical Trial Group -A5309 - Patient Remunerations Role:PI $4,710.00 Active Level:Industry

Grant: #108364 Investigators:Fichtenbaum, Carl 06-01-2012 -12-31-2013 National Institute of Allergy and Infectious Diseases ACTG PIF Year 6 Supplement Role:PI $14,604.25 Awarded Level:Federal

Grant: #UC-2013-01/HHSN272201300013I Investigators:Fichtenbaum, Carl 09-15-2013 -07-28-2020 National Institute of Allergy and Infectious Diseases Sexually Transmitted Infections Clinical Trials Group (STI-CTG) Role:PI $16,291.00 Awarded Level:Federal

Grant: #RES508646 / UM1 AI069501 Investigators:Fichtenbaum, Carl 12-10-2013 -11-30-2020 National Institute of Allergy and Infectious Diseases AIDS Clinical Trial Group Role:PI $322,151.00 Awarded Level:Federal

Grant: #110208 / UM1AI068636 Investigators:Fichtenbaum, Carl 01-01-2014 -05-31-2014 National Institute of Allergy and Infectious Diseases ACTG Protocol Funds Role:PI $120,953.00 Awarded Level:Federal

Grant: #110406 Investigators:Fichtenbaum, Carl 12-02-2013 -06-30-2014 Gilead Sciences, Inc. Long Term Effects of ARV Therapy on Change in the Bone Mineral Denisty in Infected Subjects Role:PI $1,316.00 Active Level:Federal

Grant: #224838 / U01 HL123336 Investigators:Fichtenbaum, Carl 08-08-2014 -08-30-2019 National Heart, Lung and Blood Institute Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) Role:PI $12,193.00 Active Level:Federal

Grant: #109135 / R01 HL117713 Investigators:Fichtenbaum, Carl 12-02-2013 -06-30-2014 National Heart, Lung and Blood Institute ACTG Protocol Funds A5314 Role:PI $27,050.00 Active Level:Federal

Grant: #110208-Protocol A / UM1 AI068636 Investigators:Fichtenbaum, Carl 06-01-2014 -11-30-2014 National Institute of Allergy and Infectious Diseases ACTG Protocol Funding for "A" studies Role:PI $123,651.93 Active Level:Federal

Grant: #CRM Sub / HHSN272201300013I Investigators:Fichtenbaum, Carl 10-01-2014 -09-30-2015 National Institute of Allergy and Infectious Diseases Sexually Transmitted Infections Clinical Trials Group (STI-CTG) Role:PI $16,506.77 Active Level:Federal

Grant: #224883 / R01 HL122177 Investigators:Fichtenbaum, Carl 08-15-2014 -05-31-2015 National Institute of Allergy and Infectious Diseases Effect of Low Dose Methotrexate on Arterial Inflammation in HIV- A5314 Role:PI $33,598.83 Active Level:Federal

Grant: #225707_U01 HL123336 Investigators:Fichtenbaum, Carl 08-08-2014 -04-30-2020 National Institutes of Health REPRIEVE A5332 and A5333 Role:PI $10,000.00 Awarded Level:Federal

Grant: #111670 / UM1 AI068636 Investigators:Fichtenbaum, Carl 12-01-2014 -11-30-2015 National Institute of Allergy and Infectious Diseases ACTG Protocol Funding "PF" Year 9 Role:PI $391,608.00 Active Level:Federal

Grant: #RES509526 / 2UM1AI059501-09 Yr 2 Investigators:Fichtenbaum, Carl 12-01-2014 -11-30-2015 National Institute of Allergy and Infectious Diseases AIDS Clinical Trial Group Role:PI $431,625.00 Active Level:Federal

Grant: #CW ACTG Core / AI069501 Investigators:Fichtenbaum, Carl 12-01-2015 -11-30-2016 National Institute of Allergy and Infectious Diseases AIDS Clinical Trial Group - Competitive Renewal Role:PI $374,060.00 Active Level:Federal

Grant: #SASC Investigators:Fichtenbaum, Carl 12-01-2015 -11-30-2016 National Institute of Allergy and Infectious Diseases ACTG Scientific Agenda Steering Committee (SASC) Support Role:PI $12,000.00 Active Level:Federal

Grant: #110238 / AI068636 Investigators:Fichtenbaum, Carl 03-23-2015 -11-30-2015 National Institute of Allergy and Infectious Diseases Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) Role:PI $10,821.00 Awarded Level:Federal

Grant: #137281\R01AG033057 Investigators:Fichtenbaum, Carl 09-01-2015 -08-31-2016 Cincinnati Children's Hospital Medical Center Homeostasis and function of regulatory T cells in aging Role:PI $31,600.00 Awarded Level:Private Non-Profit

Grant: #FHI360 CA-HPTN-UC-1 sub UM1AI068619 Investigators:Fichtenbaum, Carl 05-01-2016 -11-30-2016 National Institute of Allergy and Infectious Diseases HPTN 083: A Phase 2b?3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in H Role:PI $.00 Active Level:Federal

Grant: #CRB-SSS-S-16-004872 Investigators:Fichtenbaum, Carl 11-01-2015 -06-30-2016 Leidos Biomedical Research, Inc. Basic Order Agreement No. 11XS088, Task Order #Q7 Role:PI $3,400.00 Closed Level:Industry

Grant: #SSS CRB-SSS-S-16-004913 sub Leidos Bio 11XS088 sub NIAID Investigators:Fichtenbaum, Carl 06-20-2016 -09-30-2017 National Institute of Allergy and Infectious Diseases A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A Role:PI $15,600.00 Active Level:Federal

Grant: #RES511290_AI068501 Investigators:Fichtenbaum, Carl 08-01-2016 -11-30-2016 National Institute of Allergy and Infectious Diseases Case Western Equipment suplement Role:PI $35,068.00 Active Level:Federal

Grant: #CWRU FHI360 CA-HPTN-UC-1 sub UM1 AI068619 Investigators:Fichtenbaum, Carl 05-01-2016 -11-30-2017 National Institute of Allergy and Infectious Diseases HPTN 083: A Phase 2b?3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in H Role:PI $218,000.00 Awarded Level:Federal

Grant: #Rep. Women Investigators:Fichtenbaum, Carl 03-01-2016 -02-28-2017 National Institute of Allergy and Infectious Diseases Women’s Ancillary Study - Cardiovascular Disease Risk in HIV-infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction among REPRIEVE Trial Participants Role:PI $2,409.22 Awarded Level:Federal

Grant: #Rep Kidney / R01 DK108438 Investigators:Fichtenbaum, Carl 07-01-2016 -06-30-2017 National Inst of Diabetes and Digestive and Kidney Disease Effect of Pitavastatin on Kidney Function in HIV-infected Person (R01DK108438-02) - REPRIEVE Kidney Study Role:PI $35,425.00 Awarded Level:Federal

Grant: #RES511634 ACTG Core / AI069501 Investigators:Fichtenbaum, Carl 12-01-2016 -11-30-2017 National Institute of Allergy and Infectious Diseases AIDS Clinical Trial Group - Competitive Renewal Role:PI $374,060.00 Active Level:Federal

Grant: #116678 / R01 AG054366 Investigators:Fichtenbaum, Carl 08-01-2016 -05-31-2017 National Institute on Aging Pitavastatin to REduce Physical Function Impairment and Frailty in HIV (PREPARE) Role:PI $16,275.00 Awarded Level:Federal

Grant: #CWRU sub FHI360 HPTN 083 sub NIAID UM1 AI068619 Investigators:Fichtenbaum, Carl 01-01-2017 -11-30-2022 National Institute of Allergy and Infectious Diseases HPTN 083 is a Phase 2b/3 Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis Role:PI $1,259,830.00 Awarded Level:Federal

Grant: #CWRU RES512468 sub U01AI131295 Investigators:Fichtenbaum, Carl 08-09-2017 -07-31-2018 National Institute of Allergy and Infectious Diseases Resetting immune homeostasis: a non-invasive approach towards HIV eradication Role:PI $170,915.00 Active Level:Federal

Grant: #RES512798 / UM1 AI069501 Investigators:Fichtenbaum, Carl 12-01-2017 -11-30-2018 National Institute of Allergy and Infectious Diseases ACTG Core Funds Role:PI $374,030.00 Active Level:Federal

Grant: #232251 / AI123001 Investigators:Fichtenbaum, Carl 03-01-2018 -02-28-2019 National Institute of Allergy and Infectious Diseases Women’s Ancillary Study - Cardiovascular Disease Risk in HIV-infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction among REPRIEVE Trial Participants Role:PI $2,939.20 Awarded Level:Federal

Grant: #RES513645 / U01AI131295 Investigators:Fichtenbaum, Carl 08-01-2018 -07-31-2019 National Institute of Allergy and Infectious Diseases Resetting immune homeostasis: a non-invasive approach towards HIV eradication Role:PI $77,276.00 Awarded Level:Federal

Grant: #RES513848 ACTG Core-PF, HPTN PF / UM1AI069501 Investigators:Fichtenbaum, Carl 12-01-2018 -11-30-2019 National Institute of Allergy and Infectious Diseases ACTG Core Funds Role:PI $511,735.00 Awarded Level:Federal

Grant: #RES513819 / ViiV Investigators:Fichtenbaum, Carl 01-01-2017 -11-30-2018 VIIV HEALTHCARE COMPANY HPTN 083- University of Cincinnati (ViiV) Role:PI $735,241.00 Awarded Level:Industry

Grant: #110007 AEC_UM1AI068636 Investigators:Fichtenbaum, Carl 12-01-2017 -11-30-2018 National Institute of Allergy and Infectious Diseases ACTG Executive Committe Role:PI $10,000.00 Awarded Level:Federal

Grant: #1560 G WA886 Rep Chair / AI068636 Investigators:Fichtenbaum, Carl 12-01-2018 -11-30-2019 National Institute of Allergy and Infectious Diseases Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) [UM1AI068636] Vice Co-Chair on A5332 Role:PI $16,021.00 Awarded Level:Federal

Grant: #1560 G WA885 AEC / AI068636 Investigators:Fichtenbaum, Carl 12-01-2018 -11-30-2020 National Institute of Allergy and Infectious Diseases Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) [UM1AI068636] Role:PI $12,000.00 Awarded Level:Federal

Grant: #1560 B WA785 Protocol A / UM1AI068636 Investigators:Fichtenbaum, Carl 12-01-2018 -11-30-2019 National Institute of Allergy and Infectious Diseases Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) [UM1AI068636] Role:PI $325,903.00 Awarded Level:Federal

Grant: #1560BWB787 PREPARE / R01AG054366 Investigators:Fichtenbaum, Carl 06-15-2018 -05-31-2019 National Institutes of Health Pitavastatin to REduce Physical Function Impairment and Frailty in HIV (PREPARE) Role:PI $18,034.44 Active Level:Federal

Grant: #RES514327 / AI131295 Investigators:Fichtenbaum, Carl 08-01-2019 -07-31-2020 National Institute of Allergy and Infectious Diseases Resetting immune homeostasis: a non-invasive approach towards HIV eradication Role:PI $93,300.00 Awarded Level:Federal

Grant: #Rep Kidney / DK108438 Investigators:Fichtenbaum, Carl 07-01-2018 -06-30-2021 National Inst of Diabetes and Digestive and Kidney Disease Effect of Pitavastatin on Kidney Function in HIV-infected Person (R01DK108438-02) - REPRIEVE Kidney Study Role:PI $42,774.53 Awarded Level:Federal

Grant: #Janssen 63623872FLZ3001 sub BARDA HHSO10020500014C Investigators:Fichtenbaum, Carl 10-01-2019 -09-30-2020 Biomedical Advanced Research and Development Authority A Phase 3 Randomized, Double-blink, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safet of Pimodivir in Combination with the Standard-of-care Treatment in Adolescent, Adult,.... Role:PI $85,487.60 Awarded Level:Federal

Grant: #PF Sal / AI068619 Investigators:Fichtenbaum, Carl 12-01-2018 -11-30-2019 National Institute of Allergy and Infectious Diseases HPTN PF Salary supplement Role:PI $40,740.00 Awarded Level:Federal

Grant: #ACTG CORE / AI069501 Investigators:Fichtenbaum, Carl; Huaman, Moises; Sherman, Kenneth 12-01-2019 -11-30-2020 National Institute of Allergy and Infectious Diseases ACTG Core Funds, PF & HPTN Role:PI $1,110,207.00 Awarded Level:Federal

Grant: #CoVPN 3502 - UM1AI068619 Investigators:Fichtenbaum, Carl 07-01-2020 -11-30-2021 National Institute of Allergy and Infectious Diseases CoVPN 3502/ R10933-10987-COV-2069: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV Role:PI $237,750.00 Awarded Level:Federal

Grant: #FHI360-CoVPN 3001/ UM1AI068619 Investigators:Fichtenbaum, Carl; Powers-Fletcher, Margaret 07-01-2020 -06-30-2022 National Institute of Allergy and Infectious Diseases CoVPN 3001: Phase 3, SARS-CoV-2 Vaccine (Moderna TX, Inc.) Role:PI $3,269,500.00 Awarded Level:Federal

Grant: #Unknown Investigators:Fichtenbaum, Carl; Powers-Fletcher, Margaret 07-01-2020 -11-30-2020 National Institute of Allergy and Infectious Diseases COVID-19 Prevention Network (CoVPN) Role:PI $380,075.01 Active Level:Federal

Grant: #PO20002964 / UM1AI068619 CoVPN 3501 Investigators:Fichtenbaum, Carl 08-01-2020 -07-31-2021 National Institute of Allergy and Infectious Diseases A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Fac Role:PI $84,321.00 Active Level:Federal

Grant: #RES515323 / U01AI069501 Investigators:Fichtenbaum, Carl; Huaman, Moises 06-01-2020 -11-30-2020 National Institute of Allergy and Infectious Diseases ADMIN SUPPLEMENT for ACTG - CWRU Core & PF Role:PI $296,270.18 Awarded Level:Federal

Grant: #CWRU RES515587 / U01AI131295 Investigators:Fichtenbaum, Carl 08-01-2020 -09-30-2020 National Institute of Allergy and Infectious Diseases Resetting immune homeostasis: a non-invasive approach towards HIV eradication RPPR for 2020 Role:PI $224,390.00 Awarded Level:Federal

Grant: #1560 G YB694 / AI068636 Vice Chair Investigators:Fichtenbaum, Carl 12-01-2020 -11-30-2021 National Institute of Allergy and Infectious Diseases Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) AEC Role:PI $8,057.00 Awarded Level:Federal

Grant: #1560 G YB310 / AI068636 AEC Investigators:Fichtenbaum, Carl 12-01-2020 -11-30-2021 National Institute of Allergy and Infectious Diseases Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) [UM1AI068636] AEC Role:PI $4,920.00 Awarded Level:Federal

Grant: #ACTG Protocol A_AI068636 Investigators:Fichtenbaum, Carl 12-01-2020 -11-30-2027 National Institute of Allergy and Infectious Diseases Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) [UM1AI068636] Protocol A Role:PI $508,600.00 Awarded Level:Federal

Grant: #RES515922_PO20001904 Investigators:Fichtenbaum, Carl 05-01-2020 -11-30-2020 Family Health International 360 HPTN Personal Protective Equipment – HPTN Studies (Cost Reimbursable) Role:PI $26,128.00 Awarded Level:Private Non-Profit

Publications

Peer Reviewed Publications

Samineni, Divya; Fichtenbaum, Carl J (2010. ) Fenofibrate in the treatment of dyslipidemia associated with HIV infection.Expert opinion on drug metabolism & toxicology, , 6 (8 ) ,995-1004 More Information

Jacobson, Jeffrey M; Lalezari, Jacob P; Thompson, Melanie A; Fichtenbaum, Carl J; Saag, Michael S; Zingman, Barry S; D'Ambrosio, Paul; Stambler, Nancy; Rotshteyn, Yakov; Marozsan, Andre J; Maddon, Paul J; Morris, Stephen A; Olson, William C (2010. ) Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-infected Adults.Antimicrobial agents and chemotherapy, , More Information

Fichtenbaum, Carl J (2010. ) Does antiretroviral therapy increase or decrease the risk of cardiovascular disease?.Current HIV/AIDS reports, , 7 (2 ) ,92-8 More Information

Murphy, Robert L; Berzins, Baiba; Zala, Carlos; Fichtenbaum, Carl; Dube, Michael P; Guaraldi, Giovanni; Torriani, Francesca; Belsey, Elizabeth; Mitchell, Carol; Stein, James H (2010. ) Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.AIDS (London, England), , 24 (6 ) ,885-90 More Information

Lyons, Michael S; Lindsell, Christopher J; Ruffner, Andrew H; Trott, Alexander T; Fichtenbaum, Carl J (2009. ) Relationship of self-reported prior testing history to undiagnosed HIV positivity and HIV risk. Current HIV research, , 7 (6 ) ,580-8

Nyakeriga, Alice M; Fichtenbaum, Carl J; Goebel, Jens; Nicolaou, Stella A; Conforti, Laura; Chougnet, Claire A (2009. ) Engagement of the CD4 receptor affects the redistribution of Lck to the immunological synapse in primary T cells: implications for T-cell activation during human immunodeficiency virus type 1 infection.Journal of virology, , 83 (3 ) ,1193-200 More Information

Fichtenbaum, Carl J (2009. ) Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Current infectious disease reports, , 11 (1 ) ,84-92

Lyons, Michael S; Lindsell, Christopher J; Raab, Dana L; Ruffner, Andrew H; Trott, Alexander T; Fichtenbaum, Carl J (2009. ) Comparison of emergency department HIV testing data with visit or patient as the unit of analysis.Journal of medical screening, , 16 (1 ) ,29-32 More Information

Stein, James H; Komarow, Lauren; Cotter, Bruno R; Currier, Judith S; Dubé, Michael P; Fichtenbaum, Carl J; Gerschenson, Mariana; Mitchell, Carol K C; Murphy, Robert L; Squires, Kathleen; Parker, Robert A; Torriani, Francesca J (2008. ) Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy.Journal of clinical lipidology, , 2 (6 ) ,464-471 More Information

Jacobson, Jeffrey M; Saag, Michael S; Thompson, Melanie A; Fischl, Margaret A; Liporace, Ralph; Reichman, Richard C; Redfield, Robert R; Fichtenbaum, Carl J; Zingman, Barry S; Patel, Mahesh C; Murga, Jose D; Pemrick, Suzanne M; D'Ambrosio, Paul; Michael, Marti; Kroger, Hans; Ly, Hieu; Rotshteyn, Yakov; Buice, Robert; Morris, Stephen A; Stavola, Joseph J; Maddon, Paul J; Kremer, Alton B; Olson, William C (2008. ) Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.The Journal of infectious diseases, , 198 (9 ) ,1345-52 More Information

Torriani, Francesca J; Komarow, Lauren; Parker, Robert A; Cotter, Bruno R; Currier, Judith S; Dubé, Michael P; Fichtenbaum, Carl J; Gerschenson, Mariana; Mitchell, Carol K C; Murphy, Robert L; Squires, Kathleen; Stein, James H (2008. ) Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.Journal of the American College of Cardiology, , 52 (7 ) ,569-76 More Information

Dubé, Michael P; Lipshultz, Steven E; Fichtenbaum, Carl J; Greenberg, Richard; Schecter, Alison D; Fisher, Stacy D (2008. ) Effects of HIV infection and antiretroviral therapy on the heart and vasculature.Circulation, , 118 (2 ) ,e36-40 More Information

Vazquez, José A; Schranz, Jennifer A; Clark, Kay; Goldstein, Beth P; Reboli, Annette; Fichtenbaum, Carl (2008. ) A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis.Journal of acquired immune deficiency syndromes (1999), , 48 (3 ) ,304-9 More Information

Lyons, Michael S; Lindsell, Christopher J; R N, Deanna A Hawkins; Rn, Dana L Raab; Trott, Alexander T; Fichtenbaum, Carl J (2008. ) Contributions to early HIV diagnosis among patients linked to care vary by testing venue.BMC public health, , 8 ,220 More Information

Fichtenbaum, Carl J (2008. ) Editorial comment: the head bone is connected to the body bone. The AIDS reader, , 18 (5 ) ,265

Gerber, John G; Kitch, Douglas W; Fichtenbaum, Carl J; Zackin, Robert A; Charles, Stéphannie; Hogg, Evelyn; Acosta, Edward P; Connick, Elizabeth; Wohl, David; Kojic, E Milu; Benson, Constance A; Aberg, Judith A (2008. ) Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.Journal of acquired immune deficiency syndromes (1999), , 47 (4 ) ,459-66 More Information

Velilla, P A; Shata, M T; Lages, C S; Ying, J; Fichtenbaum, C J; Chougnet, C (2008. ) Effect of low-dose IL-2 immunotherapy on frequency and phenotype of regulatory T cells and NK cells in HIV/HCV-coinfected patients.AIDS research and human retroviruses, , 24 (1 ) ,52-61 More Information

Grandominico, Jodi M; Fichtenbaum, Carl J Short-term effect of HAART on blood pressure in HIV-infected individuals.HIV clinical trials, , 9 (1 ) ,52-60 More Information

de Perio, Marie A; Gomez, Francisco J; Frame, Peter T; Fichtenbaum, Carl J (2007. ) A truvada hypersensitivity reaction simulating abacavir hypersensitivity.AIDS (London, England), , 21 (16 ) ,2252-3 More Information

Lyons, Michael S; Raab, Dana L; Lindsell, Christopher J; Trott, Alexander T; Fichtenbaum, Carl J (2007. ) A novel emergency department based prevention intervention program for people living with HIV: evaluation of early experiences.BMC health services research, , 7 ,164 More Information

Lyons, Michael S; Lindsell, Christopher J; Fichtenbaum, Carl J; Camargo, Carlos A Interpreting and implementing the 2006 CDC recommendations for HIV testing in health-care settings. Public health reports (Washington, D.C. : 1974), , 122 (5 ) ,579-83

Shire, Norah J; Rouster, Susan D; Stanford, Sandra D; Blackard, Jason T; Martin, Christina M; Fichtenbaum, Carl J; Sherman, Kenneth E (2007. ) The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients.Journal of acquired immune deficiency syndromes (1999), , 44 (3 ) ,309-14 More Information

Huang, I; Leach, J L; Fichtenbaum, C J; Narayan, R K (2007. ) Osteomyelitis of the skull in early-acquired syphilis: evaluation by MR imaging and CT. AJNR. American journal of neuroradiology, , 28 (2 ) ,307-8

Evans, Scott R; Fichtenbaum, Carl J; Aberg, Judith A Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087.HIV clinical trials, , 8 (1 ) ,45-52 More Information

Wohl, D A; McComsey, G; Tebas, P; Brown, T T; Glesby, M J; Reeds, D; Shikuma, C; Mulligan, K; Dube, M; Wininger, D; Huang, J; Revuelta, M; Currier, J; Swindells, S; Fichtenbaum, C; Basar, M; Tungsiripat, M; Meyer, W; Weihe, J; Wanke, C (2006. ) Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 43 (5 ) ,645-53 More Information

Robertson, Jaime; Meier, Matthew; Wall, Jennifer; Ying, Jun; Fichtenbaum, Carl J (2006. ) Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 42 (11 ) ,1639-46 More Information

Aberg, Judith A; Rosenkranz, Susan L; Fichtenbaum, Carl J; Alston, Beverly L; Brobst, Susan W; Segal, Yoninah; Gerber, John G (2006. ) Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.AIDS (London, England), , 20 (5 ) ,725-9 More Information

Goldman, Mitchell; Cloud, Gretchen A; Wade, Karen D; Reboli, Annette C; Fichtenbaum, Carl J; Hafner, Richard; Sobel, Jack D; Powderly, William G; Patterson, Thomas F; Wheat, Lawrence J; Stein, David K; Dismukes, William E; Filler, Scott G (2005. ) A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 41 (10 ) ,1473-80 More Information

Aberg, Judith A; Zackin, Robert A; Brobst, Susan W; Evans, Scott R; Alston, Beverly L; Henry, W Keith; Glesby, Marshall J; Torriani, Francesca J; Yang, Yijun; Owens, Susan I; Fichtenbaum, Carl J (2005. ) A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.AIDS research and human retroviruses, , 21 (9 ) ,757-67 More Information

Glesby, Marshall J; Aberg, Judith A; Kendall, Michelle A; Fichtenbaum, Carl J; Hafner, Richard; Hall, Stephen; Grosskopf, Nicole; Zolopa, Andrew R; Gerber, John G (2005. ) Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.Clinical pharmacology and therapeutics, , 78 (2 ) ,143-53 More Information

Gerber, John G; Rosenkranz, Susan L; Fichtenbaum, Carl J; Vega, Jose M; Yang, Amy; Alston, Beverly L; Brobst, Susan W; Segal, Yoninah; Aberg, Judith A (2005. ) Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. Journal of acquired immune deficiency syndromes (1999), , 39 (3 ) ,307-12

Glesby, Marshall J; Bassett, Roland; Alston-Smith, Beverly; Fichtenbaum, Carl; Jacobson, Elizabeth L; Brass, Clifford; Owens, Susan; Sulkowski, Mark; Race, Elizabeth M; Sherman, Kenneth E (2005. ) Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.The Journal of infectious diseases, , 191 (5 ) ,686-93 More Information

Fichtenbaum, Carl J; Hadigan, Colleen M; Kotler, Donald P; Pierone, Gerald; Sax, Paul E; Steinhart, Corklin R; Tebas, Pablo (2005. ) Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care. IAPAC monthly, , 11 (2 ) ,38-46

Fichtenbaum, Carl J Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons. HIV clinical trials, , 5 (6 ) ,416-33

Acosta, Edward P; Wu, Hulin; Hammer, Scott M; Yu, Song; Kuritzkes, Daniel R; Walawander, Ann; Eron, Joseph J; Fichtenbaum, Carl J; Pettinelli, Carla; Neath, Denise; Ferguson, Elaine; Saah, Alfred J; Gerber, John G (2004. ) Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. Journal of acquired immune deficiency syndromes (1999), , 37 (3 ) ,1358-66

Goldman, Mitchell; Zackin, Robert; Fichtenbaum, Carl J; Skiest, Daniel J; Koletar, Susan L; Hafner, Richard; Wheat, L Joseph; Nyangweso, Peter M; Yiannoutsos, Constantin T; Schnizlein-Bick, Carol T; Owens, Susan; Aberg, Judith A (2004. ) Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 38 (10 ) ,1485-9 More Information

Zhang, Rui; Fichtenbaum, Carl J; Hildeman, David A; Lifson, Jeffrey D; Chougnet, Claire (2004. ) CD40 ligand dysregulation in HIV infection: HIV glycoprotein 120 inhibits signaling cascades upstream of CD40 ligand transcription. Journal of immunology (Baltimore, Md. : 1950), , 172 (4 ) ,2678-86

Dubé, Michael P; Stein, James H; Aberg, Judith A; Fichtenbaum, Carl J; Gerber, John G; Tashima, Karen T; Henry, W Keith; Currier, Judith S; Sprecher, Dennis; Glesby, Marshall J (2003. ) Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 37 (5 ) ,613-27 More Information

Riddle, Tara M; Fichtenbaum, Carl J; Hui, David Y (2003. ) Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice. Journal of acquired immune deficiency syndromes (1999), , 33 (5 ) ,564-70

Fichtenbaum, Carl J (2003. ) Antiretrovirals and cardiovascular disease: is HAART bad for your heart? .AIDS clinical care, , 15 (8 ) ,69-73, 76

Landon, Bruce E; Wilson, Ira B; Cohn, Susan E; Fichtenbaum, Carl J; Wong, Mitchell D; Wenger, Neil S; Bozzette, Samuel A; Shapiro, Martin F; Cleary, Paul D (2003. ) Physician specialization and antiretroviral therapy for HIV. Journal of general internal medicine, , 18 (4 ) ,233-41

Levine, Nicholas B; Kurokawa, Ryu; Fichtenbaum, Carl J; Howington, John A; Kuntz, Charles (2002. ) An immunocompetent patient with primary Scedosporium apiospermum vertebral osteomyelitis. Journal of spinal disorders & techniques, , 15 (5 ) ,425-30

Daly, Kieran R; Fichtenbaum, Carl J; Tanaka, Reiko; Linke, Michael J; O'Bert, Robert; Thullen, Timothy D; Hui, Michele S; Smulian, Alan G; Walzer, Peter D (2002. ) Serologic responses to epitopes of the major surface glycoprotein of Pneumocystis jiroveci differ in human immunodeficiency virus-infected and uninfected persons.The Journal of infectious diseases, , 186 (5 ) ,644-51 More Information

Riddle, Tara M; Schildmeyer, Nicholas M; Phan, Cam; Fichtenbaum, Carl J; Hui, David Y (2002. ) The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. Journal of lipid research, , 43 (9 ) ,1458-63

Fichtenbaum, Carl J; Gerber, John G; Rosenkranz, Susan L; Segal, Yoninah; Aberg, Judith A; Blaschke, Terrence; Alston, Beverly; Fang, Fang; Kosel, Bradley; Aweeka, Francesca (2002. ) Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS (London, England), , 16 (4 ) ,569-77

David, Max H; Hornung, Richard; Fichtenbaum, Carl J (2002. ) Ischemic cardiovascular disease in persons with human immunodeficiency virus infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 34 (1 ) ,98-102 More Information

Fichtenbaum, Carl J; Gerber, John G (2002. ) Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clinical pharmacokinetics, , 41 (14 ) ,1195-211

Landon, Bruce E; Wilson, Ira B; Wenger, Neil S; Cohn, Susan E; Fichtenbaum, Carl J; Bozzette, Samuel A; Shapiro, Martin F; Cleary, Paul D (2002. ) Specialty training and specialization among physicians who treat HIV/AIDS in the United States. Journal of general internal medicine, , 17 (1 ) ,12-22

Fichtenbaum, C J (2001. ) The evaluation and management of dyslipidemia in HIV-infected patients. AIDS clinical care, , 13 (12 ) ,113-7, 120

Riddle, T M; Kuhel, D G; Woollett, L A; Fichtenbaum, C J; Hui, D Y (2001. ) HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus.The Journal of biological chemistry, , 276 (40 ) ,37514-9 More Information

Soloway, B; Fichtenbaum, C J (2001. ) One size does not fit all. AIDS clinical care, , 13 (10 ) ,92-3

Fichtenbaum, C J; Zackin, R; Feinberg, J (2001. ) Reply to 'Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis' by Holmberg and Moorman. AIDS (London, England), , 15 (13 ) ,1745

Currier, J S; Williams, P; Feinberg, J; Becker, S; Owens, S; Fichtenbaum, C; Benson, C (2001. ) Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 32 (11 ) ,1615-22 More Information

Tantisiriwat, W; Tebas, P; Polish, L B; Casabar, E; Powderly, W G; Fichtenbaum, C J (2001. ) Elevated lactate levels in hospitalized persons with HIV infection.AIDS research and human retroviruses, , 17 (3 ) ,195-201 More Information

Fichtenbaum, C J; Zackin, R; Feinberg, J; Benson, C; Griffiths, J K (2000. ) Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. AIDS (London, England), , 14 (18 ) ,2889-93

Taylor, B N; Fichtenbaum, C; Saavedra, M; Slavinsky III, J; Swoboda, R; Wozniak, K; Arribas, A; Powderly, W; Fidel Jr, P L (2000. ) In vivo virulence of Candida albicans isolates causing mucosal infections in people infected with the human immunodeficiency virus.The Journal of infectious diseases, , 182 (3 ) ,955-9 More Information

Fichtenbaum, C J; Zackin, R; Rajicic, N; Powderly, W G; Wheat, L J; Zingman, B S (2000. ) Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295. AIDS (London, England), , 14 (7 ) ,845-52

Fichtenbaum, C J; Koletar, S; Yiannoutsos, C; Holland, F; Pottage, J; Cohn, S E; Walawander, A; Frame, P; Feinberg, J; Saag, M; Van der Horst, C; Powderly, W G (2000. ) Refractory mucosal candidiasis in advanced human immunodeficiency virus infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 30 (5 ) ,749-56 More Information

Fichtenbaum, C J; German, M; Dunagan, W C; Fraser, V J; Medoff, G; Diego, J; Powderly, W G (1999. ) A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 29 (6 ) ,1551-6 More Information

Tantisiriwat, W; Tebas, P; Clifford, D B; Powderly, W G; Fichtenbaum, C J (1999. ) Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 28 (5 ) ,1152-4 More Information

Widmer, G; Tzipori, S; Fichtenbaum, C J; Griffiths, J K (1998. ) Genotypic and phenotypic characterization of Cryptosporidium parvum isolates from people with AIDS. The Journal of infectious diseases, , 178 (3 ) ,834-40

Fichtenbaum, C J (1998. ) I hear you knockin' (but you can't come in): potent new HIV therapies are shutting out opportunistic infections. Research initiative, treatment action : RITA, , 4 (4 ) ,3-7

Cottler, L B; Compton, W M; Ben Abdallah, A; Cunningham-Williams, R; Abram, F; Fichtenbaum, C; Dotson, W (1998. ) Peer-delivered interventions reduce HIV risk behaviors among out-of-treatment drug abusers. Public health reports (Washington, D.C. : 1974), , 113 Suppl 1 ,31-41

Seydel, K B; Zhang, T; Champion, G A; Fichtenbaum, C; Swanson, P E; Tzipori, S; Griffiths, J K; Stanley, S L (1998. ) Cryptosporidium parvum infection of human intestinal xenografts in SCID mice induces production of human tumor necrosis factor alpha and interleukin-8. Infection and immunity, , 66 (5 ) ,2379-82

Fichtenbaum, C J; Powderly, W G (1998. ) Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 26 (3 ) ,556-65

Wu, A W; Jacobson, D L; Berzon, R A; Revicki, D A; van der Horst, C; Fichtenbaum, C J; Saag, M S; Lynn, L; Hardy, D; Feinberg, J (1997. ) The effect of mode of administration on medical outcomes study health ratings and EuroQol scores in AIDS. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, , 6 (1 ) ,3-10

Fichtenbaum, C J; Clifford, D B; Powderly, W G (1995. ) Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, , 10 (2 ) ,169-74

Arribas, J R; Clifford, D B; Fichtenbaum, C J; Commins, D L; Powderly, W G; Storch, G A (1995. ) Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. The Journal of infectious diseases, , 172 (2 ) ,527-31

Arribas, J R; Clifford, D B; Fichtenbaum, C J; Roberts, R L; Powderly, W G; Storch, G A (1995. ) Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma. Journal of clinical microbiology, , 33 (6 ) ,1580-3

Fichtenbaum, C J; Dunagan, W C; Powderly, W G (1995. ) Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome. Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, , 8 (1 ) ,51-7

Fichtenbaum, C J; Woeltje, K F; Powderly, W G (1994. ) Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 19 (3 ) ,417-22

Fichtenbaum, C J; Peterson, L R; Weil, G J (1993. ) Ehrlichiosis presenting as a life-threatening illness with features of the toxic shock syndrome. The American journal of medicine, , 95 (4 ) ,351-7

Fichtenbaum, C J; Ritchie, D J; Powderly, W G (1993. ) Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 16 (2 ) ,298-300

Fichtenbaum, C J; Smith, M J (1992. ) Treatment of endocarditis due to Pseudomonas aeruginosa with imipenem. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 14 (1 ) ,353-4

Afridi, S A; Fichtenbaum, C J; Taubin, H (1991. ) Review of duodenal diverticula. The American journal of gastroenterology, , 86 (8 ) ,935-8

Monteferrante, M L; Shimkin, P M; Fichtenbaum, C; Kleinman, G M; Lipow, K I Tentorial traversal by ependymoblastoma. AJNR. American journal of neuroradiology, , 12 (1 ) ,181

Fichtenbaum, C J; Kleinman, G M; Haddad, R G (1990. ) Eosinophilic granuloma of the lung presenting as a solitary pulmonary nodule. Thorax, , 45 (11 ) ,905-6

Fichtenbaum, C J; Babb, J D; Baker, D A (1988. ) Erythromycin induced cardiovascular toxicity. Connecticut medicine, , 52 (3 ) ,135-6

Samineni, Divya; Desai, Pankaj B; Sallans, Larry; Fichtenbaum, Carl J (2012. ) Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.Journal of clinical pharmacology, , 52 (6 ) ,922-31 More Information

Mohajer, Mayar Al; Lyons, Michael; King, Eileen; Pratt, Jesse; Fichtenbaum, Carl J Internal Medicine and Emergency Medicine Physicians Lack Accurate Knowledge of Current CDC HIV Testing Recommendations and Infrequently Offer HIV Testing.Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), , 11 (2 ) ,101-8 More Information

Fichtenbaum, Carl J; Evans, Scott E; Aberg, Judith A (2011. ) High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection.AIDS (London, England), , 25 (16 ) ,2053 More Information

Nyakeriga, Alice M; Ying, Jun; Shire, Norah J; Fichtenbaum, Carl J; Chougnet, Claire A (2011. ) Highly active antiretroviral therapy in patients infected with human immunodeficiency virus increases CD40 ligand expression and IL-12 production in cells ex vivo.Viral immunology, , 24 (4 ) ,281-9 More Information

Lyons, Michael S; Lindsell, Christopher J; Wayne, D Beth; Ruffner, Andrew H; Hart, Kimberly W; Fichtenbaum, Carl J; Trott, Alexander T; Sullivan, Patrick S (2011. ) Comparison of missed opportunities for earlier HIV diagnosis in 3 geographically proximate emergency departments.Annals of emergency medicine, , 58 (1 Suppl 1 ) ,S17-22.e1 More Information

Hudepohl, Nathan J; Lindsell, Christopher J; Hart, Kimberly W; Ruffner, Andrew H; Trott, Alexander T; Fichtenbaum, Carl J; Lyons, Michael S (2011. ) Effect of an emergency department HIV testing program on the proportion of emergency department patients who have been tested.Annals of emergency medicine, , 58 (1 Suppl 1 ) ,S140-4 More Information

Sitlinger, Andrea P; Lindsell, Christopher J; Ruffner, Andrew H; Wayne, D Beth; Hart, Kimberly W; Trott, Alexander T; Fichtenbaum, Carl J; Lyons, Michael S (2011. ) Preliminary program evaluation of emergency department HIV prevention counseling.Annals of emergency medicine, , 58 (1 Suppl 1 ) ,S120-5.e1-3 More Information

Ubhayakar, Nitin D; Lindsell, Christopher J; Raab, Dana L; Ruffner, Andrew H; Trott, Alexander T; Fichtenbaum, Carl J; Lyons, Michael S (2011. ) Risk, reasons for refusal, and impact of counseling on consent among ED patients declining HIV screening.The American journal of emergency medicine, , 29 (4 ) ,367-72 More Information

Fichtenbaum, Carl J (2011. ) Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection.Current infectious disease reports, , 13 (1 ) ,94-101 More Information

Presicce, Pietro; Orsborn, Kris; King, Eileen; Pratt, Jesse; Fichtenbaum, Carl J; Chougnet, Claire A (2011. ) Frequency of circulating regulatory T cells increases during chronic HIV infection and is largely controlled by highly active antiretroviral therapy.PloS one, , 6 (12 ) ,e28118 More Information

Fichtenbaum, Carl J; Yeh, Tzu-Min; Evans, Scott R; Aberg, Judith A Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.Journal of clinical lipidology, , 4 (4 ) ,279-87 More Information

Riddle, T M; Kuhel, D G; Woollett, L A; Fichtenbaum, C J; Hui, D Y (2001. ) HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus.The Journal of biological chemistry, , 276 (40 ) ,37514-9 More Information

Wohl, David A; Arnoczy, Gretchen; Fichtenbaum, Carl J; Campbell, Thomas; Taiwo, Babafemi; Hicks, Charles; McComsey, Grace A; Koletar, Susan; Sax, Paul; Tebas, Pablo; Ha, Belinda; Massengale, Kelly; Walsh, Kendall; Stein, James H (2013. ) Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.Antiviral therapy, , More Information

Lyons, Michael S; Lindsell, Christopher J; Ruffner, Andrew H; Wayne, D Beth; Hart, Kimberly W; Sperling, Matthew I; Trott, Alexander T; Fichtenbaum, Carl J (2013. ) Randomized Comparison of Universal and Targeted HIV Screening in the Emergency Department.Journal of acquired immune deficiency syndromes (1999), , More Information

McComsey, Grace A; Daar, Eric S; O'Riordan, MaryAnn; Collier, Ann C; Kosmiski, Lisa; Santana, Jorge L; Fichtenbaum, Carl J; Fink, Heidi; Sax, Paul E; Libutti, Daniel E; Gerschenson, Mariana (2013. ) Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.The Journal of infectious diseases, , 207 (4 ) ,604-11 More Information

Presicce, Pietro; Moreno-Fernandez, Maria E; Rusie, Laura K; Fichtenbaum, Carl; Chougnet, Claire A (2012. ) In vitro HIV infection impairs the capacity of myeloid dendritic cells to induce regulatory T cells.PloS one, , 7 (8 ) ,e42802 More Information

Warm, Eric J; Mathis, Bradley R; Held, Justin D; Pai, Savita; Tolentino, Jonathan; Ashbrook, Lauren; Lee, Cheryl K; Lee, David; Wood, Sharice; Fichtenbaum, Carl J; Schauer, Daniel; Munyon, Ryan; Mueller, Caroline (2014. ) Entrustment and Mapping of Observable Practice Activities for Resident Assessment.Journal of general internal medicine, , More Information

Taiwo, Babafemi; Zheng, Lu; Gallien, Sebastien; Matining, Roy M; Kuritzkes, Daniel R; Wilson, Cara C; Berzins, Baiba I; Acosta, Edward P; Bastow, Barbara; Kim, Peter S; Eron, Joseph J (2011. ) Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).AIDS (London, England), , 25 (17 ) ,2113-22 More Information

Sax, Paul E; Tierney, Camlin; Collier, Ann C; Daar, Eric S; Mollan, Katie; Budhathoki, Chakra; Godfrey, Catherine; Jahed, Nasreen C; Myers, Laurie; Katzenstein, David; Farajallah, Awny; Rooney, James F; Ha, Belinda; Woodward, William C; Feinberg, Judith; Tashima, Karen; Murphy, Robert L; Fischl, Margaret A (2011. ) Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.The Journal of infectious diseases, , 204 (8 ) ,1191-201 More Information

Brehm, Jessica H; Lalama, Christina M; Hughes, Michael D; Haubrich, Richard; Riddler, Sharon A; Sluis-Cremer, Nicolas; Mellors, John W (2011. ) Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase.Journal of acquired immune deficiency syndromes (1999), , 56 (4 ) ,344-8 More Information

McComsey, Grace A; Walker, Ulrich A; Budhathoki, Chakra B; Su, Zhaohui; Currier, Judith S; Kosmiski, Lisa; Naini, Linda G; Charles, Stéphannie; Medvik, Kathy; Aberg, Judith A (2010. ) Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229.AIDS (London, England), , 24 (16 ) ,2507-15 More Information

Flexner, Charles; Tierney, Camlin; Gross, Robert; Andrade, Adriana; Lalama, Christina; Eshleman, Susan H; Aberg, Judith; Sanne, Ian; Parsons, Teresa; Kashuba, Angela; Rosenkranz, Susan L; Kmack, Anne; Ferguson, Elaine; Dehlinger, Marjorie; Mildvan, Donna (2010. ) Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 50 (7 ) ,1041-52 More Information

Gross, Robert; Tierney, Camlin; Andrade, Adriana; Lalama, Christina; Rosenkranz, Susan; Eshleman, Susan H; Flanigan, Timothy; Santana, Jorge; Salomon, Nadim; Reisler, Ronald; Wiggins, Ilene; Hogg, Evelyn; Flexner, Charles; Mildvan, Donna (2009. ) Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.Archives of internal medicine, , 169 (13 ) ,1224-32 More Information

Haubrich, Richard H; Riddler, Sharon A; DiRienzo, A Gregory; Komarow, Lauren; Powderly, William G; Klingman, Karin; Garren, Kevin W; Butcher, David L; Rooney, James F; Haas, David W; Mellors, John W; Havlir, Diane V (2009. ) Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.AIDS (London, England), , 23 (9 ) ,1109-18 More Information

Riddler, Sharon A; Haubrich, Richard; DiRienzo, A Gregory; Peeples, Lynne; Powderly, William G; Klingman, Karin L; Garren, Kevin W; George, Tania; Rooney, James F; Brizz, Barbara; Lalloo, Umesh G; Murphy, Robert L; Swindells, Susan; Havlir, Diane; Mellors, John W (2008. ) Class-sparing regimens for initial treatment of HIV-1 infection.The New England journal of medicine, , 358 (20 ) ,2095-106 More Information

Sandler, Netanya G; Zhang, Xinyan; Bosch, Ronald J; Funderburg, Nicholas T; Choi, Andrew I; Robinson, Janet K; Fine, Derek M; Coombs, Robert W; Jacobson, Jeffrey M; Landay, Alan L; Douek, Daniel C; Tressler, Randall; Read, Sarah W; Wilson, Cara C; Deeks, Steven G; Lederman, Michael M; Gandhi, Rajesh T (2014. ) Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection.The Journal of infectious diseases, , 210 (10 ) ,1549-54 More Information

Lennox, J L; Landovitz, R J; Ribaudo, H J; Ofotokun, I; Na, L H; Godfrey, C; Kuritzkes, D R; Sagar, M; Brown, T T; Cohn, S E; McComsey, G A; Aweeka, F; Fichtenbaum, C J; Presti, R M; Koletar, S L; Haas, D W; Patterson, K B; Benson, C A; Baugh, B P; Leavitt, R Y; Rooney, J F; Seekins, D; Currier, J S (2014. ) Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.Annals of internal medicine, , 161 (7 ) ,I-22 More Information

Lennox, Jeffrey L; Landovitz, Raphael J; Ribaudo, Heather J; Ofotokun, Ighovwerha; Na, Lumine H; Godfrey, Catherine; Kuritzkes, Daniel R; Sagar, Manish; Brown, Todd T; Cohn, Susan E; McComsey, Grace A; Aweeka, Francesca; Fichtenbaum, Carl J; Presti, Rachel M; Koletar, Susan L; Haas, David W; Patterson, Kristine B; Benson, Constance A; Baugh, Bryan P; Leavitt, Randi Y; Rooney, James F; Seekins, Daniel; Currier, Judith S (2014. ) Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.Annals of internal medicine, , 161 (7 ) ,461-71 More Information

Moschella, Phillip C; Hart, Kimberly W; Ruffner, Andrew H; Lindsell, Christopher J; Wayne, D Beth; Sperling, Matthew I; Trott, Alexander T; Fichtenbaum, Carl J; Lyons, Michael S (2014. ) Prevalence of undiagnosed acute and chronic HIV in a lower-prevalence urban emergency department.American journal of public health, , 104 (9 ) ,1695-9 More Information

Taiwo, Babafemi O; Chan, Ellen S; Fichtenbaum, Carl J; Ribaudo, Heather; Tsibris, Athe; Klingman, Karin L; Eron, Joseph J; Berzins, Baiba; Robertson, Kevin; Landay, Alan; Ofotokun, Igho; Brown, Todd (2015. ) Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 61 (7 ) ,1179-88 More Information

Dubé, Michael P; Komarow, Lauren; Fichtenbaum, Carl J; Cadden, Joseph J; Overton, Edgar T; Hodis, Howard N; Currier, Judith S; Stein, James H (2015. ) Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 61 (5 ) ,840-9 More Information

Tashima, Karen T; Mollan, Katie R; Na, Lumine; Gandhi, Rajesh T; Klingman, Karin L; Fichtenbaum, Carl J; Andrade, Adriana; Johnson, Victoria A; Eron, Joseph J; Smeaton, Laura; Haubrich, Richard H (2015. ) Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity.HIV clinical trials, , 16 (4 ) ,147-56 More Information

Longenecker, Chris T; Kitch, Douglas; Sax, Paul E; Daar, Eric S; Tierney, Camlin; Gupta, Samir K; McComsey, Grace A (2015. ) Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s.Journal of acquired immune deficiency syndromes (1999), , 69 (2 ) ,168-77 More Information

Gianella, Sara; Marconi, Vincent C; Berzins, Baiba; Benson, Constance A; Sax, Paul; Fichtenbaum, Carl J; Wilkin, Timothy; Vargas, Millie; Deng, Qianqian; Oliveira, Michelli F; Moser, Carlee; Taiwo, Babafemi O (2018. ) Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy.Journal of acquired immune deficiency syndromes (1999), , 79 (5 ) ,e112-e114 More Information

Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge; Gupta, Samir K; McComsey, Grace A; Klingman, Karin L; Fichtenbaum, Carl J; Brown, Todd T; Taiwo, Babafemi O (2018. ) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy.AIDS (London, England), , 32 (17 ) ,2517-2524 More Information

Cahn, Pedro; Madero, Juan Sierra; Arribas, José Ramón; Antinori, Andrea; Ortiz, Roberto; Clarke, Amanda E; Hung, Chien-Ching; Rockstroh, Jürgen K; Girard, Pierre-Marie; Sievers, Jörg; Man, Choy; Currie, Alexander; Underwood, Mark; Tenorio, Allan R; Pappa, Keith; Wynne, Brian; Fettiplace, Anna; Gartland, Martin; Aboud, Michael; Smith, Kimberly (2018. ) Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.Lancet (London, England), , More Information

Hsue, Priscilla Y; Ribaudo, Heather J; Deeks, Steven G; Bell, Tanvir; Ridker, Paul M; Fichtenbaum, Carl; Daar, Eric S; Havlir, Diane; Yeh, Eunice; Tawakol, Ahmed; Lederman, Michael; Currier, Judith S; Stein, James H (2018. ) Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , More Information

Huaman, Moises A; Henson, David; Rondan, Paola L; Ticona, Eduardo; Miranda, Gustavo; Kryscio, Richard J; Mugruza, Raquel; Aranda, Ernesto; Ticona, Cesar; Abarca, Susan; Heredia, Paula; Aguirre, Andres; Sterling, Timothy R; Garvy, Beth A; Fichtenbaum, Carl J (2018. ) Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma in Lima, Peru.PloS one, , 13 (9 ) ,e0202191 More Information

Rai, Mohammad A; Pannek, Sam; Fichtenbaum, Carl J (2018. ) Emerging reverse transcriptase inhibitors for HIV-1 infection.Expert opinion on emerging drugs, , 23 (2 ) ,149-157 More Information

Taiwo, Babafemi O; Marconi, Vincent C; Berzins, Baiba; Moser, Carlee B; Nyaku, Amesika N; Fichtenbaum, Carl J; Benson, Constance A; Wilkin, Timothy; Koletar, Susan L; Colasanti, Jonathan; Acosta, Edward P; Li, Jonathan Z; Sax, Paul E (2018. ) Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 66 (11 ) ,1794-1797 More Information

Utay, Netanya S; Kitch, Douglas W; Yeh, Eunice; Fichtenbaum, Carl J; Lederman, Michael M; Estes, Jacob D; Deleage, Claire; Magyar, Clara; Nelson, Scott D; Klingman, Karen L; Bastow, Barbara; Luque, Amneris E; McComsey, Grace A; Douek, Daniel C; Currier, Judith S; Lake, Jordan E (2018. ) Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone.The Journal of infectious diseases, , 217 (11 ) ,1770-1781 More Information

Huaman, Moises A; Ticona, Eduardo; Miranda, Gustavo; Kryscio, Richard J; Mugruza, Raquel; Aranda, Ernesto; Rondan, Paola L; Henson, David; Ticona, Cesar; Sterling, Timothy R; Fichtenbaum, Carl J; Garvy, Beth A (2018. ) The Relationship Between Latent Tuberculosis Infection and Acute Myocardial Infarction.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 66 (6 ) ,886-892 More Information

Shive, Carey L; Judge, Chelsey J; Clagett, Brian; Kalayjian, Robert C; Osborn, Melissa; Sherman, Kenneth E; Fichtenbaum, Carl; Gandhi, Rajesh T; Kang, Minhee; Popkin, Daniel L; Sieg, Scott F; Lederman, Michael M; Rodriguez, Benigno; Anthony, Donald D (2018. ) Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.Vaccine, , 36 (4 ) ,453-460 More Information

Perazzo, Joseph D; Webel, Allison R; Fichtenbaum, Carl J; McComsey, Grace A Bone Health in People Living With HIV: The Role of Exercise and Directions for Future Research.The Journal of the Association of Nurses in AIDS Care : JANAC, , 29 (2 ) ,330-337 More Information

Orkin, Chloe; Molina, Jean-Michel; Negredo, Eugenia; Arribas, José R; Gathe, Joseph; Eron, Joseph J; Van Landuyt, Erika; Lathouwers, Erkki; Hufkens, Veerle; Petrovic, Romana; Vanveggel, Simon; Opsomer, Magda (2018. ) Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.The lancet. HIV, , 5 (1 ) ,e23-e34 More Information

Rentz, Michael F; Ruffner, Andrew H; Ancona, Rachel M; Hart, Kimberly W; Kues, John R; Barczak, Christopher M; Lindsell, Christopher J; Fichtenbaum, Carl J; Lyons, Michael S (2017. ) Pilot Integration of HIV Screening and Healthcare Settings with Multi- Component Social Network and Partner Testing for HIV Detection.Current HIV research, , 15 (5 ) ,372-381 More Information

Asmuth, David M; Hinkle, John E; LaMarca, Anthony; Fichtenbaum, Carl J; Somsouk, Ma; Utay, Netanya S; Shaw, Audrey L; Petschow, Bryon W; Detzel, Christopher J; Weaver, Eric M Evaluation of oral serum-derived bovine immunoglobulins in HIV-infected patients with chronic idiopathic diarrhea.HIV clinical trials, , 18 (5-6 ) ,205-213 More Information

Cahn, Pedro; Kaplan, Richard; Sax, Paul E; Squires, Kathleen; Molina, Jean-Michel; Avihingsanon, Anchalee; Ratanasuwan, Winai; Rojas, Evelyn; Rassool, Mohammed; Bloch, Mark; Vandekerckhove, Linos; Ruane, Peter; Yazdanpanah, Yazdan; Katlama, Christine; Xu, Xia; Rodgers, Anthony; East, Lilly; Wenning, Larissa; Rawlins, Sandy; Homony, Brenda; Sklar, Peter; Nguyen, Bach-Yen; Leavitt, Randi; Teppler, Hedy (2017. ) Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.The lancet. HIV, , 4 (11 ) ,e486-e494 More Information

Huaman, M A; Kryscio, R J; Fichtenbaum, C J; Henson, D; Salt, E; Sterling, T R; Garvy, B A (2017. ) Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis.Epidemiology and infection, , 145 (7 ) ,1363-1367 More Information

Huaman, Moises A; Deepe, George S; Fichtenbaum, Carl J Elevated Circulating Concentrations of Interferon-Gamma in Latent Tuberculosis Infection.Pathogens & immunity, , 1 (2 ) ,291-303 More Information

Chan, Ellen S; Landay, Alan L; Brown, Todd T; Ribaudo, Heather J; Mirmonsef, Paria; Ofotokun, Igho; Weitzmann, M Neale; Martinson, Jeffrey; Klingman, Karin L; Eron, Joseph J; Fichtenbaum, Carl J; Plants, Jill; Taiwo, Babafemi O (2016. ) Differential CD4+ cell count increase and CD4+?: ?CD8+ ratio normalization with maraviroc compared with tenofovir.AIDS (London, England), , 30 (13 ) ,2091-7 More Information

Stellbrink, Hans-Jürgen; Le Fevre, Eric; Carr, Andrew; Saag, Michael S; Mukwaya, Geoffrey; Nozza, Silvia; Valluri, Srinivas Rao; Vourvahis, Manoli; Rinehart, Alex R; McFadyen, Lynn; Fichtenbaum, Carl; Clark, Andrew; Craig, Charles; Fang, Annie F; Heera, Jayvant (2016. ) Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.AIDS (London, England), , 30 (8 ) ,1229-38 More Information

Lyons, Michael S; Kunnathur, Vidhya A; Rouster, Susan D; Hart, Kimberly W; Sperling, Matthew I; Fichtenbaum, Carl J; Sherman, Kenneth E (2016. ) Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 62 (9 ) ,1066-71 More Information

Jacobson, Jeffrey M; Zheng, Lu; Wilson, Cara C; Tebas, Pablo; Matining, Roy M; Egan, Michael A; Eldridge, John; Landay, Alan L; Clifford, David B; Luetkemeyer, Anne F; Tiu, Jennifer; Martinez, Ana L; Janik, Jennifer; Spitz, Teresa A; Hural, John; McElrath, Juliana; Frahm, Nicole (2016. ) The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.Journal of acquired immune deficiency syndromes (1999), , 71 (2 ) ,163-71 More Information

Tashima, Karen T; Smeaton, Laura M; Fichtenbaum, Carl J; Andrade, Adriana; Eron, Joseph J; Gandhi, Rajesh T; Johnson, Victoria A; Klingman, Karin L; Ritz, Justin; Hodder, Sally; Santana, Jorge L; Wilkin, Timothy; Haubrich, Richard H (2015. ) HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial.Annals of internal medicine, , 163 (12 ) ,908-17 More Information

Honors and Awards

1993 Peterson, LR and Fichten baum, CJ. Human Ehrlichiosis presenting as a life-threatening illness. First prize, American College of Physicians Associates Clinical Research Competition. ACP Spring Meeting, Washington DC

1992 -1994 Trainee, National Institute of Drug Abuse, Washington University

1996 John T. Carey Young Investigator Award, Adult AIDS Clinical Trials Group

2005 Top Physician, Guide to America's Top Physicians. Consumers' Research Council of America, Second Edition

2005 Top Doctors Award in Infectious Diseases, Cincinnati Magazine

2006 Top Physician, Guide to America's Top Physicians. Consumers' Research Council of America, Third Edition

2006 Top Doctors Award in Infectious Diseases, Cincinnati Magazine

2007 Health Care Heroes, Winner, Cincinnati Business Courier

2007 Top Physician, Guide to America's Top Physicians. Consumers' Research Council of America, Fourth Edition

2007 Top Doctors Award in Infectious Diseases, Cincinnati Magazine

2007 First Prize, Research Poster Competition. Bobula SM, Fichtenbaum CJ. Mismanagement of HIV-1 Infected Adults with Acute Febrile Illnesses by Cd4+ Count Risk Stratification. Ohio ACP Chapter Meeting

2008 Top Physician, Guide to America's Top Physicians. Consumers' Research Council of America, Fifth Edition

2008 Top Doctors Award in Infectious Diseases, Cincinnati Magazine

2009 Top Physician, Guide to America's Top Physicians. Consumers' Research Council of America, Sixth Edition

2009 Top Doctors Award in Infectious Diseases, Cincinnati Magazine

Keywords

Infectious Diseases, AIDS-HIV, HIV Infection

Contact Information

Academic - UC Health Holmes Hospital
Room 3114
Cincinnati  Ohio, 45219
Phone: 513-584-6977
Fax: 513-584-6386
carl.fichtenbaum@uc.edu